Convergence of risk prediction models in follicular lymphoma


Disclosures: 1. This work was supported by a Terry Fox Research Institute New Investigator Award (Grant #1079), a Leukemia & Lymphoma Society of Canada Operating Grant (Grant #513421) and the Princess Margaret Cancer Foundation. 2. Laurie Sehn - Consultancy and Honoraria from Roche/Genentech, Abbvie, Amgen, Celgene, Janssen, Lundbeck, Seattle Genetics, Merck, TG Therapeutics, Morphosys, and Karyopharm; Clementine Sarkozy - Travel support from Takeda (for ASH 2016), research funding from Takeda and Roche/Genentech, honoraria from Roche / Genentech and Celgene; Randy D. Gascoyne - consulting for Roche; Oliver Weigert - Roche and Novartis: research support for work outside of submitted work; Christian Steidl - Consulting for Hoffmann-La Roche, Seattle Genetics and Affimed Therapeutics; expert testimony for Juno Therapeutics. Research funding: BMS, Tioma; Robert Kridel - Travel support from Roche. Research funding from Gilead.

Contributions: A.S. and R.K. designed the research, analyzed the data, and wrote the manuscript; A.M. and R.K. performed the research; S.B., T. L., V. J., M. B., O. C. L., L.H.S., R.D.G., O.W. and C.S., collected and contributed samples and data. All authors approved the final manuscript draft.